In a prospective study including 34 HER2+ and 16 HER2− BC patients, an SUVmax cutoff of 3.2 in 89Zr-trastuzumab PET/CT showed a sensitivity of 76% and specificity of 62% to distinguish HER2+ from HER2− lesions [82]. This evidence concerns the gene ERBB2 and breast cancer.